For the readers interested in the stock health of Intec Pharma Ltd (NTEC). It is currently valued at $4.40. When the transactions were called off in the previous session, Stock hit the highs of $4.80, after setting-off with the price of $3.87. Company’s stock value dipped to $3.80 during the trading on the day. When the trading was stopped its value was $3.89.
Recently in News on December 9, 2020, Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma. Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces it has entered into a feasibility agreement with GW Research Limited (“GW”), London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Intec Pharma Ltd had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.80 on 01/11/21, with the lowest value was $3.43 for the same time period, recorded on 01/04/21.
Intec Pharma Ltd (NTEC) full year performance was -57.05%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intec Pharma Ltd shares are logging -72.18% during the 52-week period from high price, and 100.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.20 and $15.82.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3476850 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Intec Pharma Ltd (NTEC) recorded performance in the market was 27.54%, having the revenues showcasing -18.22% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 17.37M, as it employees total of 38 workers.
Analysts verdict on Intec Pharma Ltd (NTEC)
During the last month, 0 analysts gave the Intec Pharma Ltd a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.38, with a change in the price was noted -2.29. In a similar fashion, Intec Pharma Ltd posted a movement of -34.19% for the period of last 100 days, recording 603,515 in trading volumes.
Intec Pharma Ltd (NTEC): Technical Analysis
Raw Stochastic average of Intec Pharma Ltd in the period of last 50 days is set at 44.72%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 74.19%. In the last 20 days, the company’s Stochastic %K was 42.74% and its Stochastic %D was recorded 28.29%.
Let’s take a glance in the erstwhile performances of Intec Pharma Ltd, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 27.54%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -17.54%, alongside a downfall of -57.05% for the period of the last 12 months. The shares increased approximately by 21.21% in the 7-day charts and went up by -5.17% in the period of the last 30 days. Common stock shares were lifted by -18.22% during last recorded quarter.